REG - Sareum Holdings PLC - Results of AGM

Sareum HoldingsAnnouncement

16/12/2022 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221216:nRSP0537Ka&default-theme=true

RNS Number : 0537K  Sareum Holdings PLC  16 December 2022

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 16 December 2022 - Sareum Holdings plc (AIM: SAR), a
biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer , held its Annual General Meeting ("AGM") today
and all resolutions were duly passed. Details of the voting results are shown
in the table below.

 

 Ordinary Resolutions                                                           Votes For  %      Votes Against  %      Votes Total  % of ISC Voted  Votes Withheld
 1. Receive and adopt Report of the Directors and financial statements for the  6,255,275  99.82  11,023         0.18   6,270,831    9.21            4,533
 year
 2. Receive and adopt Renumeration Committee report for the year                5,232,943  85.28  902,951        14.72  6,270,831    9.21            134,937
 3. Re-elect Dr John Reader as Director of the Company                          6,085,556  98.87  69,338         1.13   6,270,831    9.21            115,937
 4. Appoint Shipleys LLP as auditor                                             5,618,405  91.55  518,753        8.45   6,270,831    9.21            133,673
 5. Directors' authority to allot new shares                                    5,345,322  86.08  864,630        13.92  6,270,831    9.21            60,879
 Special Resolution
 6. Directors' authority to allot equity securities for cash                    5,316,094  85.61  893,858        14.39  6,270,831    9.21            60,879

 

The full text of each of the resolutions is set out in the Notice of AGM,
available in the Investors section of the Company's website
(www.sareum.com/investors (http://www.sareum.com/investors/document-centre/) )

 

- Ends -

 

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO / Alex Harrison, Investor Relations   01223 497700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                             020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Oliver Duckworth                          020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                            020 3764 2341

 Consilium Strategic Communications (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki       0203 709 5700

 

About Sareum

Sareum is a specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases. The Company aims to generate value through licensing its candidates
to international pharmaceutical and biotechnology companies at the preclinical
or early clinical trials stage.

Sareum is focused on advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors into clinical
development as potential new therapies for autoimmune diseases (with an
initial focus on psoriasis), respiratory symptoms arising from viral
infections and cancer immunotherapy. Sareum is also eligible to receive
certain milestone payments and future royalties on SRA737, a clinical-stage,
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell
replication and DNA damage repair mechanisms. SRA737 was licensed to Sierra
Oncology, which was acquired by GSK in June 2022.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFFEFIMEESEFE